X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (157) 157
index medicus (138) 138
humans (129) 129
female (111) 111
breast cancer (89) 89
breast neoplasms - pathology (59) 59
middle aged (57) 57
breast neoplasms - drug therapy (53) 53
cancer (46) 46
chemotherapy (40) 40
adult (39) 39
aged (39) 39
care and treatment (36) 36
treatment outcome (34) 34
metastasis (30) 30
trastuzumab (30) 30
survival (29) 29
breast neoplasms - therapy (26) 26
breast neoplasms - mortality (25) 25
medicine & public health (24) 24
antineoplastic combined chemotherapy protocols - therapeutic use (23) 23
research (22) 22
breast neoplasms - genetics (21) 21
prognosis (21) 21
breast neoplasms - metabolism (20) 20
tumors (20) 20
aged, 80 and over (19) 19
health aspects (19) 19
women (19) 19
analysis (18) 18
article (18) 18
neoplasm staging (18) 18
neoplasm metastasis (17) 17
bone neoplasms - secondary (16) 16
clinical trials (16) 16
disease-free survival (16) 16
patients (16) 16
risk factors (16) 16
diagnosis (15) 15
therapy (15) 15
antineoplastic agents - therapeutic use (14) 14
kaplan-meier estimate (14) 14
male (14) 14
receptor, erbb-2 - metabolism (14) 14
retrospective studies (14) 14
patient outcomes (13) 13
skin and connective tissue diseases (13) 13
cell line, tumor (12) 12
erbb-2 protein (12) 12
pain - etiology (12) 12
quality of life (12) 12
surgery (12) 12
animals (11) 11
cells (11) 11
metastases (11) 11
risk (11) 11
survival analysis (11) 11
adjuvant chemotherapy (10) 10
bone neoplasms - drug therapy (10) 10
breast (10) 10
cancer patients (10) 10
double-blind (10) 10
endocrine therapy (10) 10
estrogen (10) 10
metastatic breast cancer (10) 10
pain (10) 10
proportional hazards models (10) 10
quality-of-life (10) 10
administration, oral (9) 9
antineoplastic agents - administration & dosage (9) 9
antineoplastic agents - adverse effects (9) 9
biomarkers (9) 9
clinical neurology (9) 9
clinical trials as topic (9) 9
combination (9) 9
combined modality therapy (9) 9
epidermal growth factor (9) 9
expression (9) 9
gene expression (9) 9
medicine, general & internal (9) 9
multivariate analysis (9) 9
randomized controlled trials as topic (9) 9
tamoxifen (9) 9
cancer pain (8) 8
cancer therapies (8) 8
disease progression (8) 8
docetaxel (8) 8
gene expression profiling (8) 8
medical research (8) 8
neoplasms - complications (8) 8
pain management (8) 8
phase-ii (8) 8
subtypes (8) 8
toxicity (8) 8
trial (8) 8
abridged index medicus (7) 7
antibodies, monoclonal - therapeutic use (7) 7
antibodies, monoclonal, humanized (7) 7
apoptosis (7) 7
biomarkers, tumor - genetics (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC Medicine, ISSN 1741-7015, 09/2015, Volume 13, Issue 1, pp. 223 - 223
The field of breast cancer had witnessed clear improvements in survival and less morbidity over the last few decades owing to earlier detection as a result of... 
Clinical trials | Breast cancer | Translational | Molecular | Targeted therapy | TAMOXIFEN | PREVENTION | EXERCISE | PALBOCICLIB | MEDICINE, GENERAL & INTERNAL | OBESITY | POLYMORPHISMS | THERAPY | RESISTANCE | Medical Oncology | Female | Research | Breast Neoplasms | Humans | Drug therapy | Metastasis | Index Medicus
Journal Article
The Breast Journal, ISSN 1075-122X, 05/2012, Volume 18, Issue 3, pp. 201 - 202
Journal Article
The Lancet Oncology, ISSN 1470-2045, 07/2018, Volume 19, Issue 7, pp. 904 - 915
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2017, Volume 23, Issue 18, pp. 5658 - 5658
Journal Article
Nature Communications, ISSN 2041-1723, 06/2017, Volume 8, Issue 1, pp. 15916 - 15916
Deregulation of the cell cycle machinery is a hallmark of cancer. While CDK4/6 inhibitors are FDA approved (palbociclib) for treating advanced estrogen... 
PALBOCICLIB | APOPTOSIS | CELLS | OXIDATIVE STRESS | ADVANCED BREAST-CANCER | MULTIDISCIPLINARY SCIENCES | REGULATES AUTOPHAGY | LETROZOLE | G1 ARREST | DEPENDENT KINASE INHIBITOR | ANTITUMOR-ACTIVITY | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Cyclin-Dependent Kinase 4 - genetics | Humans | Cellular Senescence - drug effects | Cytoplasm - metabolism | Antineoplastic Agents - administration & dosage | Breast Neoplasms - physiopathology | Cyclin E - genetics | Autophagy - drug effects | Breast Neoplasms - metabolism | Female | Cytoplasm - genetics | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyridines - administration & dosage | Retinoblastoma Protein - metabolism | Cyclin-Dependent Kinase 6 - genetics | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Animals | Breast Neoplasms - genetics | Mice, Nude | Retinoblastoma Protein - genetics | Cell Line, Tumor | Mice | Cyclin E - metabolism | Cell Cycle - drug effects | Cytoplasm - drug effects | Senescence | Deregulation | Estrogens | Estrogen | Estrogen receptors | Breast cancer | In vitro testing | Autophagy | Machinery | Cyclin-dependent kinase 4 | Inhibitors | Cell cycle | Xenografts | Biomarkers | Breast | Cyclin E | Bioindicators | Inhibition | Phagocytosis | Tumors | Cancer | Index Medicus
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 4/2012, Volume 132, Issue 3, pp. 1049 - 1062
Journal Article
Cancer Research, ISSN 0008-5472, 10/2014, Volume 74, Issue 19 Supplement, pp. 1971 - 1971
Journal Article
BMC Cancer, ISSN 1471-2407, 06/2016, Volume 16, Issue 1, pp. 352 - 352
Journal Article
Oncology, ISSN 0890-9091, 10/2011, Volume 25, Issue 11, pp. 1028 - 1030
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 16, pp. 4780 - 4792
Purpose: Inflammatory breast cancer (IBC), diagnosed clinically, and triple-negative breast cancer (TNBC), diagnosed by molecular receptor status, are the two... 
CELL LUNG-CANCER | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | SELUMETINIB AZD6244 | INDUCED APOPTOSIS | IN-VIVO | DOWN-REGULATION | LEUKEMIA-CELLS | PHASE-II | EXPRESSION | XENOGRAFT MODEL | Niacinamide - analogs & derivatives | Apoptosis - drug effects | Humans | Histone Deacetylase Inhibitors - administration & dosage | Myeloid Cell Leukemia Sequence 1 Protein - metabolism | Apoptosis - genetics | Triple Negative Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Proto-Oncogene Proteins c-bcl-2 - metabolism | Benzamides - administration & dosage | Inflammatory Breast Neoplasms - drug therapy | Inflammatory Breast Neoplasms - metabolism | Female | Benzamides - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Cell Proliferation - genetics | Pyridines - administration & dosage | Kaplan-Meier Estimate | Inflammatory Breast Neoplasms - genetics | Breast Neoplasms - drug therapy | Myeloid Cell Leukemia Sequence 1 Protein - genetics | Niacinamide - administration & dosage | Drug Synergism | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Breast Neoplasms - genetics | Triple Negative Breast Neoplasms - genetics | Mice, Nude | Triple Negative Breast Neoplasms - metabolism | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Niacinamide - pharmacology | Proto-Oncogene Proteins c-bcl-2 - genetics | Therapy | Histone deacetylase | Target recognition | Bcl-2 protein | Extracellular signal-regulated kinase | Breast cancer | Inflammation | Gene expression | Synergism | Mcl-1 protein | Degradation | Mitochondria | Inhibitors | Experimental design | Cell death | Cell lines | Breast | In vivo methods and tests | Inhibition | Health risk assessment | Cancer | Apoptosis | Index Medicus | Entinostat | Inflammatory breast cancer | Pimasertib | PMAIP1 | NOXA | Triple-negative breast cancer | MCL1
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 7/2019, Volume 176, Issue 1, pp. 227 - 234
Lapatinib (L) is approved in combination with capecitabine or letrozole for patients with trastuzumab-resistant HER2-positive metastatic breast cancer (MBC).... 
Medicine & Public Health | Pertuzumab | Oncology | T-DM1 | Breast cancer | Metastatic | Lapatinib | HER2 | Trastuzumab | Care and treatment | Relapse | Epidermal growth factor | Metastasis | Health aspects | Cancer | Diseases
Journal Article